Drs J7akobsson, Berg, and Svensson comment: Drs Beattie and MacKenzie raise an important question. In our paper we have used the same criteria for renal scarring as used by Rushton et al. I The results of both studies are similar. We consider a defect, still present on a DMSA scan after two years as a thinning or flattening of the renal parenchyma, and on the same site as the original insult, to be a sign of irreversible renal damage. Moreover, a scar situated on the front or on the back of the kidney will not disturb the cortical outline when only a posterior projection is used, as was the case in our study. It is difficult to believe that proximal tubular cells not functioning after two years from the insult will return to normal function. The anecdotal experience described by Dr Beattie and Dr MacKenzie may be explained by hypertrophy of remaining healthy proximal tubular cells resulting in an improvement of DMSA uptake, obscuring the original defect.
As the use of DMSA scan is becoming more popular, one will find signs of permanent renal damage in children after acute pyelonephritis more frequently than previously when intravenous urography was used. We will not know for some time how we should interpret many of these defects seen on a DMSA scan but not on intravenous urography in terms of risk for later complications. The term 'renal scarring' is well defined as it appears on intravenous urography and the term 'parenchymal reduction' is used for kidneys with signs of parenchymal thinning only. Maybe we should proceed in the same manner with regard to findings on DMSA scan, reserving the term renal scarring for kidneys with reduced DMSA uptake without preservation of the cortical outline, and parenchymal reduction or thinning for those with reduced uptake with preservation of the cortical outline. In both cases, however, the kidney is permanently damaged. 
